Basic and clinical studies on S-1108

Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Toshiyuki Ishimaru, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Satoshi Kuboi, Yoshiyuki Niho

Research output: Contribution to journalArticle

Abstract

We performed basic and clinical studies on S-1108, a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of S-1006, the active substance of S-1108, were determined with an inoculum size of 106 cells/ml. The MIC90 of S-1006 was 0. 78μg/ml for Staphylococcus aureus, 100< for Enterococcus faecalis, 0.78 for Escherichia coli, 6.25 for Klebsiella pneumoniae, 25 for Enterobacter spp., 50 for Serratia marcescens and Citrobacter freundii, and 100 for Pseudomonas aeruginosa. Its activity against S. aureus was greater than that of the new oral cephems. On the other hand, its activity against gram-negative bacilli was the same as that of the new oral cephems and there were few strains highly-resistant to S-1006. 2) Clinical efficacy Four patients with pneumonia, 2 with acute bronchitis, 5 with chronic bronchitis, 2 with tonsillitis, and 1 with cystitis were treated with S-1108, The patients were treated with a daily dose of 150-600 mg for 2-40 days. The clinical response was excellent in 3, good in 5, fair in 3, poor in 1, and unknown in one patient. The efficacy rate was 69.3%. Adverse reactions were dysphoria (1 patient), and swelling of the vulva and nipple (1 patient), but there were no changes in the laboratory findings.

Original languageEnglish
Pages (from-to)326-333
Number of pages8
JournalCHEMOTHERAPY
Volume41
DOIs
Publication statusPublished - Jan 1 1993

Fingerprint

S 1108
Staphylococcus aureus
Citrobacter freundii
Tonsillitis
Enterobacter
Serratia marcescens
Cystitis
Vulva
Nipples
Bronchitis
Enterococcus faecalis
Chronic Bronchitis
Klebsiella pneumoniae
Cephalosporins
Cell Size
Pseudomonas aeruginosa
Bacillus
Pneumonia
Clinical Studies
Escherichia coli

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Kumagai, Y., Ishimaru, T., Takaki, K., Shimono, N., ... Niho, Y. (1993). Basic and clinical studies on S-1108. CHEMOTHERAPY, 41, 326-333. https://doi.org/10.11250/chemotherapy1953.41.Supplement1_326

Basic and clinical studies on S-1108. / Sawae, Yoshiro; Okada, Kaoru; Kumagai, Yukio; Ishimaru, Toshiyuki; Takaki, Koji; Shimono, Nobuyuki; Misumi, Hiroyasu; Eguchi, Katsuhiko; Kuboi, Satoshi; Niho, Yoshiyuki.

In: CHEMOTHERAPY, Vol. 41, 01.01.1993, p. 326-333.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Kumagai, Y, Ishimaru, T, Takaki, K, Shimono, N, Misumi, H, Eguchi, K, Kuboi, S & Niho, Y 1993, 'Basic and clinical studies on S-1108', CHEMOTHERAPY, vol. 41, pp. 326-333. https://doi.org/10.11250/chemotherapy1953.41.Supplement1_326
Sawae Y, Okada K, Kumagai Y, Ishimaru T, Takaki K, Shimono N et al. Basic and clinical studies on S-1108. CHEMOTHERAPY. 1993 Jan 1;41:326-333. https://doi.org/10.11250/chemotherapy1953.41.Supplement1_326
Sawae, Yoshiro ; Okada, Kaoru ; Kumagai, Yukio ; Ishimaru, Toshiyuki ; Takaki, Koji ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Eguchi, Katsuhiko ; Kuboi, Satoshi ; Niho, Yoshiyuki. / Basic and clinical studies on S-1108. In: CHEMOTHERAPY. 1993 ; Vol. 41. pp. 326-333.
@article{06aea0876ea940089e08f127a68478fd,
title = "Basic and clinical studies on S-1108",
abstract = "We performed basic and clinical studies on S-1108, a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of S-1006, the active substance of S-1108, were determined with an inoculum size of 106 cells/ml. The MIC90 of S-1006 was 0. 78μg/ml for Staphylococcus aureus, 100< for Enterococcus faecalis, 0.78 for Escherichia coli, 6.25 for Klebsiella pneumoniae, 25 for Enterobacter spp., 50 for Serratia marcescens and Citrobacter freundii, and 100 for Pseudomonas aeruginosa. Its activity against S. aureus was greater than that of the new oral cephems. On the other hand, its activity against gram-negative bacilli was the same as that of the new oral cephems and there were few strains highly-resistant to S-1006. 2) Clinical efficacy Four patients with pneumonia, 2 with acute bronchitis, 5 with chronic bronchitis, 2 with tonsillitis, and 1 with cystitis were treated with S-1108, The patients were treated with a daily dose of 150-600 mg for 2-40 days. The clinical response was excellent in 3, good in 5, fair in 3, poor in 1, and unknown in one patient. The efficacy rate was 69.3{\%}. Adverse reactions were dysphoria (1 patient), and swelling of the vulva and nipple (1 patient), but there were no changes in the laboratory findings.",
author = "Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Toshiyuki Ishimaru and Koji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Katsuhiko Eguchi and Satoshi Kuboi and Yoshiyuki Niho",
year = "1993",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.41.Supplement1_326",
language = "English",
volume = "41",
pages = "326--333",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on S-1108

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Ishimaru, Toshiyuki

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Eguchi, Katsuhiko

AU - Kuboi, Satoshi

AU - Niho, Yoshiyuki

PY - 1993/1/1

Y1 - 1993/1/1

N2 - We performed basic and clinical studies on S-1108, a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of S-1006, the active substance of S-1108, were determined with an inoculum size of 106 cells/ml. The MIC90 of S-1006 was 0. 78μg/ml for Staphylococcus aureus, 100< for Enterococcus faecalis, 0.78 for Escherichia coli, 6.25 for Klebsiella pneumoniae, 25 for Enterobacter spp., 50 for Serratia marcescens and Citrobacter freundii, and 100 for Pseudomonas aeruginosa. Its activity against S. aureus was greater than that of the new oral cephems. On the other hand, its activity against gram-negative bacilli was the same as that of the new oral cephems and there were few strains highly-resistant to S-1006. 2) Clinical efficacy Four patients with pneumonia, 2 with acute bronchitis, 5 with chronic bronchitis, 2 with tonsillitis, and 1 with cystitis were treated with S-1108, The patients were treated with a daily dose of 150-600 mg for 2-40 days. The clinical response was excellent in 3, good in 5, fair in 3, poor in 1, and unknown in one patient. The efficacy rate was 69.3%. Adverse reactions were dysphoria (1 patient), and swelling of the vulva and nipple (1 patient), but there were no changes in the laboratory findings.

AB - We performed basic and clinical studies on S-1108, a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of S-1006, the active substance of S-1108, were determined with an inoculum size of 106 cells/ml. The MIC90 of S-1006 was 0. 78μg/ml for Staphylococcus aureus, 100< for Enterococcus faecalis, 0.78 for Escherichia coli, 6.25 for Klebsiella pneumoniae, 25 for Enterobacter spp., 50 for Serratia marcescens and Citrobacter freundii, and 100 for Pseudomonas aeruginosa. Its activity against S. aureus was greater than that of the new oral cephems. On the other hand, its activity against gram-negative bacilli was the same as that of the new oral cephems and there were few strains highly-resistant to S-1006. 2) Clinical efficacy Four patients with pneumonia, 2 with acute bronchitis, 5 with chronic bronchitis, 2 with tonsillitis, and 1 with cystitis were treated with S-1108, The patients were treated with a daily dose of 150-600 mg for 2-40 days. The clinical response was excellent in 3, good in 5, fair in 3, poor in 1, and unknown in one patient. The efficacy rate was 69.3%. Adverse reactions were dysphoria (1 patient), and swelling of the vulva and nipple (1 patient), but there were no changes in the laboratory findings.

UR - http://www.scopus.com/inward/record.url?scp=0027291944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027291944&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.41.Supplement1_326

DO - 10.11250/chemotherapy1953.41.Supplement1_326

M3 - Article

VL - 41

SP - 326

EP - 333

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -